Novartis’ Entresto is on course to become the first drug to be approved in the US for a form of heart failure that is notoriously hard to treat effectively, despite missing the mark in a phase 3 ...

As the ink dries on the US approval of Novartis' heart failure treatment Entresto, talk has quickly shifted to pricing issues, and possible outcomes-based plans, rather than the drug's very ...

Novartis markets and sells a combination therapy of valsartan and sacubitril under the brand name Entresto® for the treatment of various forms ...

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.

Here are some frequently asked questions about the drug’s side effects and their answers. How do side effects of Verquvo compare with those of Entresto? Verquvo and Entresto (sacubitril ...

MSN Laboratories Pvt. Ltd. urged the Federal Circuit to reconsider a three-judge panel’s January ruling that revived a patent for Novartis AG’s blockbuster heart-disease drug Entresto. The Jan. 10 ...

Novartis AG is fighting MSN Laboratories Pvt. Ltd.'s efforts to pull a revived patent from Entresto’s entry in the FDA’s Orange Book, urging a Delaware federal judge to toss the generic-drug maker’s ...

Verquvo and Entresto are both prescription drugs used to help prevent complications of heart failure. Verquvo is taken once per day. Entresto is taken twice per day. Various factors could affect ...

The Swiss pharma giant’s cardiometabolic product lineup is currently anchored by Entresto, a heart failure drug that accounted for $7.8 billion in worldwide sales in 2024, a 30% increase ...

Healthcare experts urge India to rewrite clinical trial rules to boost global market share India should take a page from the playbook of countries such as China and Australia if it wants a larger ...